Molecular Diagnostics

分子诊断

• 批准号: 8744817
• 负责人: JAMES Lewis ZEHNDER
• 金额: $ 23.23万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8744817
• 关键词: Animal Model; B cell repertoire; Biological; Biological Assay; Bone Marrow Transplantation; Chemistry; Clinical; Custom; Data; Detection of Minimal Residual Disease; Diagnostic; Disease; Disease Progression; Early Diagnosis; Ensure; Gene Rearrangement; Goals; Gold; Immune; Instruction; Intervention; Investigational Therapies; Massive Parallel Sequencing; Methods; Molecular; Molecular Analysis; Molecular Profiling; Monitor; Patients; Performance; Play; Procedures; Program Research Project Grants; Recurrence; Relapse; Research Personnel; Residual Neoplasm; Reverse Transcriptase Polymerase Chain Reaction; Role; Services; Specimen; Technology; Testing; Time; Tissue Sample; Transplantation; Treatment outcome; Work; base; clinical care; cost; hematopoietic cell transplantation; improved; innovation; leukemia/lymphoma; meetings; molecular marker; molecular pathology; next generation; next generation sequencing; novel; preclinical study; programs; reconstitution; response; tool

The role of the Molecular Pathology Core is to support investigators in the Program Project Grant by providing dedicated molecular biological analyses for effective assessment of disease states, the molecular basis of response to therapy both in patients and in animal models, and the analysis of immune reconstitution following transplant interventions. The services provided by this Core are those that extend beyond routine preclinical studies and standard clinical care. This Core provides molecular testing for projects that monitor treatment outcomes, detect eariy disease recurrence and minimal disease states. Rapid and quantitative assessment of experimental therapies is necessary for accelerated and accurate analyses of potential efficacy. Quantitative assessment of minimal residual disease will be performed using TaqMan chemistry for a robust assessment of disease response and potential recurrence on clinical specimens. The core will utilize novel, massively parallel next generation sequencing technology in addition to the standard real-time PCR methods to improve detection of minimal residual disease and provide an assessment of immune reconstitution. The centralized performance of the molecular procedures by this Core will avoid duplication of efforts in the program and ensure timely, efficient and consistently high quality results.

分子病理学核心的作用是通过提供专门的分子生物学分析来支持计划项目资助中的研究人员，以有效评估疾病状态，患者和动物模型中治疗反应的分子基础，以及移植干预后免疫重建的分析。该核心提供的服务是那些扩展 超越常规临床前研究和标准临床护理。该核心为监测治疗结果、检测早期疾病复发和最小疾病状态的项目提供分子检测。 快速和定量评估的实验疗法是必要的加速和准确的分析潜在的疗效。将使用TaqMan化学对微小残留病进行定量评估，以稳健评估临床治疗后的疾病缓解和潜在复发。 标本除了标准的实时PCR方法外，该核心还将利用新的大规模并行下一代测序技术，以改善微小残留病的检测，并提供免疫重建的评估。该核心的分子程序的集中执行将避免项目中的重复工作，并确保及时、高效和一致的高质量 结果